Abstracts tagged "Psoriatic arthritis and vaccines"

Abstract Number: 2614 • 2018 ACR/ARHP Annual Meeting
The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
Ori Elkayam¹, Devy Zisman², Ilana Kaufman³, Uri Arad⁴, Mark Berman⁵, Victoria Furer⁶, Yael Lahat¹, Or Carmi¹, Amir Haddad⁷, Muna Elias⁷, Daphna Paran¹ and Michal Mandelbaum⁸, ¹Department of rheumatology, Tel Aviv medical center and the Sackler Faculty of medicine, Tel Aviv University, Tel Aviv, Israel, ²Technion, Rheumatology Unit Carmel Medical Center, Haifa, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ⁷Rheumatology Unit Carmel Medical Center, Haifa, Israel, ⁸Sheba medical center, Ramat Gan, Israel
Background/Purpose: The humoral response to vaccination may be affected by the use of immunosuppressive drugs. The effect of secukinumab on the humoral response of vaccines…
Abstract Number: 352 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Vaccination Against seasonal 2012 Influenza Virus Among Patients With Psoriatic Arthritis and Psoriasis
Arik Polackek¹, Yuri Korobko¹, Noa Madar-Balakirski¹, Uri Arad², David Levartovsky³, Ilana Kaufman⁴, Marina Anouk⁵, Irena Litinsky⁶, Ella Mendelson⁷, Daphna Paran⁸, Hagit Matz⁹, Dan Caspi¹⁰, Michal Mandelbaum¹¹ and Ori Elkayam¹², ¹Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Rheumatology, Tel Aviv Medical Ctr, Tel Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, ⁶Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, ⁷Central Virology Laboratory, Sheba Medical Center, Ramat Gan, Israel, ⁸Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, ⁹Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹⁰Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹¹Central Virology Department, Sheba Medical Center, Tel Aviv, Israel, ¹²Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (Pso) are considered to be immunosuppressed and are therefore recommended to receive vaccination against seasonal influenza. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].